Vir Biotechnology (VIR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$303.2M

Revenue (quarter)

$238.9M

Revenue growth (year over year)

+19582.54%

Gross profit (trailing twelve months)

$303.2M

Gross margin

100.00%

Net income (trailing twelve months)

−$251.7M

Net income (quarter)

$80.1M

Net income growth (year over year)

+172.17%

Net margin

−83.00%

Return on equity

−26.08%

EPS (trailing twelve months)

−$1.77

Book value per share

$5.81

P/E (trailing twelve months)

—

Price to book

1.79

Debt to assets

19.12%

Payout ratio

—

Dividend yield

—

Company profile

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

• Is Vir Biotechnology (VIR) profitable?

  No. Vir Biotechnology reported a net loss of $251.7M over the trailing twelve months.

• How much revenue does Vir Biotechnology (VIR) make?

  Vir Biotechnology generated $303.2M in revenue over the trailing twelve months, up 19582.54% year over year.

• How do I buy stock in Vir Biotechnology (VIR)?

  VIR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.